Alzinova AB Sustainability Reports
Alzinova AB is a Swedish clinical-stage biopharmaceutical company engaged in the discovery and development of therapeutics and active immunotherapies for the treatment of Alzheimer's disease. Its pipeline features a proprietary peptide technology platform used to target neurotoxic amyloid-beta oligomers.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300K3IMVT20EK2S13
FIGI: BBG00B4QSSC8
8 reports from 2016 to 2025
